This article is more than 5 years old. Information may no longer be current.

Laser for glaucoma, retinal disorders granted U.S. marketing approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MOUNTAIN VIEW, Calif. — An infrared diode laser photocoagulator for use in treating retinal disorders and glaucoma has been granted 501(k) marketing approval by the Food and Drug Administration, the laser’s marketer announced in a press release.

The Iris Medical IQ 810 has been designed to perform traditional and minimum intensity photocoagulation, said marketer Iridex in the press release.

Features of the IQ 810 include interactive software for setup and operation of the machine, customization of laser output and settings, and an integrated systems diagnostic. The software offers ophthalmologists “quick access” to several operating modes and advanced pulse modalities, Iridex noted.

The laser is commercially available now and will be featured at the Iridex booth next week at the American Academy of Ophthalmology meeting.